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Abstract 
Interleukin l/I was found to stimulate arachidonic acid release, and the synthesis and secretion of type II phospholipase A2 by rabbit articular 
chondrocytes in vitro. Interleukin l/I had no effect on the level of cytosolic phospholipase A2 mRNA. Insulin-like growth factors, which help stabilize 
the cartilage matrix, reduced the effect of interleukin 1j.I on type II phospholipase A2 activity and mRNA level, and decreased the Interleukin 
l@timulated arachidonic acid release to the basal values. This suggests that type II phospholipase A2 plays a key role in arachidonic acid release 
from rabbit articular chondrocytes and that insulin-like growth factors counteract he effect of interleukin I/?. They may therefore be considered as 
potential antiinflammatory agents. 
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1. Introduction 
The synthesis of eicosanoids in many cells depends on 
the availability of free arachidonic acid (AA) and the 
major source of free AA is its release from membrane 
phospholipids by a cellular phospholipase A2 (PLA2). 
This release of AA from membrane phospholipids eems 
to be the rate-limiting step in production of lipid media- 
tors during inflammatory disorders [l]. Little is known 
about the identity and the regulation of the PLA2 re- 
sponsible for the releasing of AA from activated cells. 
Two main types of cellular PLA2 have been cloned to 
date. One has a high molecular weight (85 kDa), and is 
found in the cytosol of such cells as macrophages [2], 
synoviocytes [3], mesangial cells [4] or fibroblasts [5]. 
This PLA2 is highly specific for arachidonic acid, and is 
activated by a receptor-specific pathway [6]. The other 
type of PLA2 has a low molecular weight (14 kDa) 
(sPLA2) [7,8] and is secreted by chondrocytes [9, lo], syn- 
oviocytes [3], and mesangial cells [l 11. 
High amounts of sPLA2 have been found in the syn- 
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Abbreviations: AA: arachidonic acid; IGF: insulin-like growth factor; 
IL,/% interleukin lp; PLAZ: phospholipase A2; sPLA2: secreted PLAZ; 
cPLA2: cytosolic PLA2 
ovial fluid [ 121 and cartilage matrix [ 131 of patients suf- 
fering from joint diseases with local inflammation such 
as rheumatoid arthritis. It has recently been suggested 
that the chondrocytes are the main source of this protein 
[ 141. Among the factors which regulate PLA2 production 
by chondrocytes or other connective tissue cells, inter- 
leukin lp (IL@), a proinflammatory cytokine, has been 
shown to induce AA release from both chondrocytes [151 
and synoviocytes [16], and induce the expression of the 
sPLA2 gene in chondrocytes [9] and the cPLA2 gene in 
synoviocytes [3]. IL&I also causes cartilage destruction 
inducing an imbalance between matrix synthesis and 
degradation by chondrocytes [17,181. 
In contrast, growth factors such as insulin-like growth 
factor 1 and 2 (IGF, and IGF,), which are also secreted 
by cartilage and connective tissue cells, favor cartilage 
differentiation by stimulating chondrocyte matrix pro- 
duction [19]. But no information is available as to 
whether there is any interaction between IGFs and IL$ 
in cartilage cells. 
This study was therefore designed to investigate 
whether IGF, and IGF, interfere with the regulation of 
inflammatory markers induced by IL@ in chondrocytes. 
ILJ stimulated the AA release and the expression of 
sPLA2 gene, but appeared to have no effect on cPLA2. 
IGF, and IGF2 reduced the effects of IL,/3 on sPLA2 
mRNA level in chondrocytes, the sPLA2 activity, and 
the amount of AA release. 
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2. Materials and methods 
2. I. Chondrocyte culture 
Four-week-old rabbits were killed and the shoulders, knees and fem- 
oral heads were dissected out under sterile conditions [20]. The articular 
cartilage was removed and cut into small pieces (< 0.5 mm2) and di- 
gested successively at 37°C with 0.05% testicular hyaluronidase in 
HAM’s F12 medium (from Flobio) for 15 min, 0.25% trypsin for 30 min 
and 0.2% clostridial collagenase for 90 min. The hyaluronidase, collage- 
nase and trypsin were purchased from Boehringer. The resulting sus- 
pension of chondrocytes was seeded into 75 cm’ flasks (4 x lo5 cells per 
flask) or into 24-well cell culture Dlates (2 x 10“ cells aer well) in HAM’s 
F12 $upplemented with 10% fe&l calf‘serum, 10 U’I/ml penicillin and 
100 pg/rnl streptomycin. The cells were maintained at 37°C in 5% CO*, 
and the culture medium was changed every 2-3 days. The cells reached 
confluency within &7 days. Cells cultured in 24-well plates were used 
to measure arachidonic acid release, whereas cells in 75 cm’ flasks were 
used for mRNA extraction and PLA2 assay. 
2.2. Arachidonic acid release 
Confluent cells were incubated in a serum-free DMEM medium for 
24 h and then with 0.5 &i/ml [3H]arachidonic acid (3,000 Ci/mmol, 
Amersham) in DMEM supplemented with 0.1% IGF-free bovine serum 
albumin (Sigma) at 37°C for 1 h. The cells were washed three times with 
phosphate-buffered saline. They were then incubated with human re- 
combinant IL@ (0.1-100 ng/ml) (Immugenex, USA), and-or IGF, or 
IGF, (l&100 @ml) (Genzyme by Tebu, France). In some experiments, 
cells were incubated with the peptides for periods of 5 min-24 h. Ali- 
quots of the supernatant were removed and the arachidonic acid release 
measured. At the end of the incubation, the cells were washed, scraped 
free and sonicated. The radioactivity of cells and media was quantified 
by scintillation counting. Results are expressed as percentages of the 
release under basal conditions in order to compare all experiments. 
2.3. Phospholipase A2 assyv, 
The phospholipase A2 activity secreted into media was measured on 
100 ~1 samples using 2 nmol of fluorescent substrate (I-palmitoyl2(10- 
pyr&ylde&noyl)-Sn glycero-3-monomethyl phosphatidic acid, Inter- 
chim) as described by Radvanyi [21] and modified by Pernas [22]. The 
specificity of the phospholipase A2 activity measured was assessed by 
the hydrolysis of labeled substrate L3 phosphatidyl ethanolamine, l-
acyl-2-[l-‘4C]arachidonyl (50 mCi/mmol, Amersham) [23]. 
2.4. Northern blotting 
Total cell RNA was extracted [24] from confluent chondrocytes cul- 
tured in 75 cm’ flasks The RNA was fractionated on a 1% agarose gel 
containing 2.2 M formaldehyde and transferred onto a nylon mem- 
brane (Hybond N, Amersham, France). RNA was immobilized by 
baking at 80°C for 2 h. Hybridization was performed with the rapid 
hyb-buffer kit (Amersham, France) using full-length cDNA probes for 
human placental 14 kDa type II PLA2 [22] and human cytosolic 85 kDa 
PLA2 prepared by polymerase chain reaction from U937 cell mRNA 
accordingto Clark [2]. A 28s oligonucleotide probe was used as control 
in the Northern blots [25]. Secreted PLA2 and cPLA2 cDNA probes 
were labeled with la-32P]dCTP (Amersham, France, 3,000 CYmmol) by 
random priming labeling system (Amersham, France). The membranes 
were prehybridized for 15 min, and then hybridized at 65°C for 90 min, 
washed with 0.1% SDS in 2 x SSC at room temperature, followed by 
two washes with 0.1% SDS in 0.1 x SSC at 65°C for 15 min each. The 
filters were then autoradiographed at -80°C for 18-72 h using MP 
hypertilm (Amersham, France). The resulting autoradiographs were 
scanned with a laser densitometer (2202 ultrascan, LKB). Results are 
expressed as the ratio of 500 bp (sPLA2) optic density (OD) to the 
corresponding 28s OD. RNA from C ,*, cells overexpressing type II 
PLA2 and from U937 cells were used as positive control for 14 kDa 
sPLA2 and 85 kDa cPLA2, respectively. 
2.5. Statistical analysis 
When necessary, Student’s t-test was used for statistical analysis. 
3. Results 
The release of AA was first studied as a marker of the 
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Fig. 1. Effects of IL#, IGF, and IGFz on arachidonic acid release from 
prelabelled rabbit chondrocytes. The cells were labelled with [‘Hlara- 
chidonic acid as described in Section 2. The arachidonic acid released 
into the medium after a 24 h stimulation by effecters is expressed as% 
of the release under basal conditions. The shaded areas indicate the 
basal release (mean f S.D. of 5 experiments); 100% control cell release 
corresponds to 13% + 2% of total radioactivity. (A) The effects of IL@, 
IGF, or IGF,. (B) The effects of IGF, and IGF, on arachidonic acid 
release induced by 25 ng/ml IL,p. Data are the means t S.E.M. of 5 
experiments each performed in triplicate. *P < 0.05 
inflammatory effect of ILJ? on chondrocytes. Incubation 
of chondrocytes with IL,B (0.1-100 &ml) for 24 h re- 
sulted in a dose-dependent increase in AA release (Fig. 
1A) which was significant at 25 and 50 r&ml IL,B 
(around 200% of the basal release), but not significant 
between 50 and 100 &ml. The decrease at 100 ng/ml 
could be due to this concentration of IL,/? being toxic as 
shown by a decrease in Trypan blue exclusion (not 
shown). 
Incubation with IGF, or IGF, alone reduced the re- 
lease of AA by 25 I 15% at all the peptide concentra- 
tions used (lo-100 ng/ml). IGF, or IGF, (25 or 50 ng/ml) 
significantly reduced the amount of AA released in re- 
sponse to 25 ng/ml IL,p, back to the basal level 
(P c 0.05) (Fig. 1B). IL,/3 did not stimulate the release 
of AA before 24 h (not shown). In contrast, the time 
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4. Discussion 
Fig. 2. Time course of the effect of 25 &ml IGF, (0) and 25 ng/ml IGF, 
(0) on the basal arachidonic acid release. Values are the means + S.D. 
of 2 experiments each performed in triplicate. The shaded areas indicate 
the basal release (means + S.D. of 5 experiments). The corresponding 
control releases were: 3% + 1.7% for 30 min; 4.1% + 1.9% for 60 min; 
7.9% f 4.4% for 120 min; 10.2% f 1.9% for 4 h and 13% f 2% for 24 
h. 
course of the effects of IGF, or IGF, on AA release 
appeared to be biphasic: a sharp and rapid decrease 
down to 50% below the control values occurred 15 min 
after adding the peptides and AA release returned to the 
basal level between 60 and 120 min. A second decrease 
occured 4 h later, reaching a minimum (50% of control) 
at 24h (Fig. 2). 
Chondrocyte mRNA PLA2 transcripts hybridized 
with two specific probes, one identifying sPLA2 mRNA 
expressed as a 500 bp band in Cl27 transfected cells and 
the other identifying cPLA2 mRNA expressed as a 3200 
bp band in U937 cells (Fig. 3). No chondrocyte sPLA2 
mRNA was detected under basal conditions, whereas 
cPLA2 mRNA was clearly observed. Incubation with 10 
r&ml IL,/? for 24 h stimulated production of sPLA2 
mRNA, but did not alter the cPLA2 mRNA level. The 
chondrocyte cPLA2 mRNA was not studied further. The 
expression of sPLA2 mRNA induced by ILJ was dose- 
dependent between 0.1 to 10 &ml (Fig. 4) after incuba- 
tion for 4 h and 24 h with IL,/?. The sPLA2 signal was 
decreased by incubation with 25 &ml IGF, or IGF, 
plus 10 ng/ml IL@ (Fig. 4B). This inhibitory effect of 
IGF, or IGF, was more pronounced after 4 h (35% and 
54%, respectively) than after 24 h (20% and lo%, respec- 
tively). Secreted PLA2 enzymic activity was not detected 
in the culture media of chondrocytes incubated under 
basal conditions (Fig. 5). Cells incubated with 10 to 50 
ng/ml IL,/3 for 24 h released considerable sPLA2 activity 
into the culture medium. IGF, or IGF, (25 &ml) signif- 
icantly reduced (-65%) the sPLA2 activity induced by 25 
&ml IL,/? alone (P < 0.001). 
IL,/? had parallel effects on AA release, sPLA2 
mRNA level and sPLA2 activity in rabbit articular chon- 
drocytes. These results are consistent with those reported 
by others [9,10] for similar cell types. Hulkower et al. [3] 
recently found that no increase on sPLA2 activity could 
account for the increased PGE, production induced by 
ILip in synovial fibroblasts. They showed that ILJ stim- 
ulated cPLA2 activity in parallel with PGE2 release. A 
similar result was found in rat mesangial cells stimulated 
by IL,jI [4]. But this does not seem to be the case in rabbit 
articular chondrocytes, as IL&I had no effect on the 
cPLA2 mRNA level after 24 h (Fig. 3), or on ara- 
chidonyl-specific PLA2 activity in the cytosol (not 
shown). This seems to rule out the involvement of cPLA2 
in the stimulation of AA release by IL,/? in rabbit articu- 
lar chondrocytes. However, the IL&stimulated AA re- 
lease might not be fully explained by the increase in 
medium sPLA2, because sPLA2 alone does not appear 
to release AA from prelabelled cells [22]. Therefore, 
IL,/?, besides inducing sPLA2 synthesis might target 
another mechanism stimulating AA release. This mecha- 
nism might involve another unknown PLA2, or the acti- 
vation of another pathway increasing the effect of sPLA2 
on chondrocytes. Such an amplification of sPLA2-medi- 
ated release of AA has been described in response to 
protein kinase C stimulation in human T lymphocytes 
[26] and in mouse fibroblasts overexpressing human 
sPLA2 [22]. 
The data also demonstrate that IGFs inhibit the re- 
lease of AA. The basal AA release was significantly re- 
duced within 15 min of adding IGF, or IGF,. The chon- 
drocytes contained detectable amounts of cPLA2 
mRNA but not of sPLA2 mRNA under the experimental 
conditions used. The mechanism of this short term effect 
of IGFs is still unknown. One of the rapid receptor- 
mediated mechanism modulating cPLA2 activity seems 
a b c 
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Fig. 3. Northern blot analysis of sPLA2 (500 bp) and cPLA2 (3,200 bp) 
mRNA in unstimulated and IL&treated chondrocytes. Lane a: posi- 
tive controls for sPLA2, mRNA from C,r, cells transfected by human 
type II PLA2 and for cPLA2, mRNA from Ug3, cells. Lane b: unstim- 
ulated chondrocytes. Lane c: chondrocytes incubated with 10 ng/ml 
IL,jI for 24 h before RNA extraction. 15 pug of total RNA were 
analysed as described in Section 2. Each lane represents the hybridiza- 
tion of the same blot with the cDNA probes of human sPLA2 and 
cPLA2, respectively. 
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Fig. 4. Effects of IL#, IGF, and IGF, on mRNA levels of sPLA2. Total RNA was extracted and analysed as described in Section 2. The labelled 
bands were quantified by scanning the autoradiograms. Data are expressed as the ratio of 500 bp (sPLA2) OD to the corresponding 28 S OD. (A) 
Effect of a 4h incubation with IL,B and its modulation by IGF, and IGF,. (B) Effect of a 24 h incubation with ILip, and its modulation by IGF, 
and IGF,. Lane a: positive control for sPLA2: C2, cells transfected by human sPLA2. lane b: unstimulated chondrocytes. Lane c: chondrocytes 
incubated with 0.1 ng/ml IL,. Lane d: 1 ng/ml ILJ. Lane e: 10 @ml IL,/I. Lane f: 10 ng/ml IL,jl + 25 @ml IGF,jI. Lane g: 10 r&ml IL,/l + 25 
ng/ml IGF,. 
to be its phosphorylation by mitogen-activated protein 
kinase [6]. IGF, might cause negative modulation of 
chondrocyte cPLA2 by a phosphorylation- 
dephosphorylation mechanism. 
Lastly, incubation of chondrocytes with IGF, or IGF, 
for 24 h inhibited the IL&induced sPLA2 gene expres- 
sion and enzyme activity, as well as AA release. Further 
experiments are needed to elucidate the mechanism by 
which IL,/3 is inhibited. It could involve inhibition of 
IL,/3 receptor synthesis, as occurs with Transforming 
Growth Factor p (TGFB) [27], or an interaction between 
the signalling pathways of IGFl and IL&modulating 
sPLA2 synthesis and secretion. This is, to our knowl- 
edge, the first demonstration that both IGF peptides 
interfere with induced inflammatory processes at con- 
centrations which are known to stimulate chondrocyte 
matrix production [19,28]. 
Some of the negative effect of ILip on joint inflamma- 
tion could be due to the increased synthesis of sPLA2 by 
articular chondrocytes, as sPLA2 can induce experimen- 
tal arthritis [29,30]. It is therefore possible that IGFs, in 
addition to their anabolic effect on cartilage, act as anti- 
inflammatory or anti-arthritis factors in joints. 
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Fig. 5. PLA2 released into the medium from cells incubated with IL,/?, 
IGF, and IGF,. The chondrocytes were incubated with the agents for 
24 h, the medium was removed, and the PLA2 activity was measured 
as described in Section 2. Data are the means f S.E.M. of 3 experiments 
performed in triplicate. ND = not detectable. ***P < 0.001. 
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